Bioengineered blood vessel implanted into arm of patient with end-stage kidney disease

Washington, June 9 (ANI): Doctors at Duke University Hospital created a bioengineered blood vessel and implanted it into the arm of a patient with end-stage kidney disease.

The procedure, the first US clinical trial to test the safety and effectiveness of the bioengineered blood vessel, is a milestone in the field of tissue engineering.

The new vein is an off-the-shelf, human cell-based product with no biological properties that would cause organ rejection.

Using technology developed at Duke and at a spin-off company it started called Humacyte, the vein is engineered by cultivating donated human cells on a tubular scaffold to form a vessel.

The vessel is then cleansed of the qualities that might trigger an immune response.

In pre-clinical tests, the veins have performed better than other synthetic and animal-based implants.

"It's exciting to see something you've worked on for so long become a reality. We talk about translational technology - developing ideas from the laboratory to clinical practice - and this only happens where there is the multi-disciplinary support and collaboration to cultivate it," Jeffrey H. Lawson, M.D., PhD, a vascular surgeon and vascular biologist at Duke Medicine who helped develop the technology and performed the implantation, said. (ANI)


Get stories like this on the Yahoo app and discover more every day.
Download it now.